Jefferies rates Parexel at underperform

Parexel International Corp. was given an underperform rating by Jefferies & Co., Inc. analyst David Windley. Parexel reported $150 million in net revenues and earnings per share of $0.19 for the December quarter. Management's revenue and earnings-per-share forecasts were $142 to $147 million and $0.15 to $0.18, respectively. Shares of the Waltham, Mass., biopharmaceutical company were up $3.50 or 16.38%, at $24.87 on volume of 1,181,232 shares versus the three-month running average of 106,627 shares. (Nasdaq: PRXL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.